Skip to main content
PharmaCielo Ltd. logo

PharmaCielo Ltd. — Investor Relations & Filings

Ticker · PCLO ISIN · CA71716K1012 LEI · 5493002XOFWMT83TYQ57 TSXV Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2024-08-16 Regulatory Filings
Country CA Canada
Listing TSXV PCLO

About PharmaCielo Ltd.

https://www.pharmacielo.com/

PharmaCielo Ltd. is a global supplier specializing in the cultivation, processing, and distribution of medicinal-grade cannabis extracts and dried flower. The company focuses on ethical and sustainable production, aiming to be a leading partner in the global medicinal cannabis market. Utilizing ideal equatorial conditions, PharmaCielo operates large-scale, high-efficiency production facilities, including 12 hectares of open-air greenhouses, enabling four full crops annually for reliable supply. Its product portfolio includes standardized extracts, such as high-purity CBD Isolate, and both psychoactive and non-psychoactive derivatives. Production adheres to pharmaceutical-quality standards, supported by proprietary genetics maintained in a tissue culture lab and advanced processing facilities ensuring consistency and safety.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CEO of PharmaCielo Ltd. regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2024. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The document does not contain the actual interim financial statements or substantive financial data but is an officer certification related to the interim filings. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is short (2979 characters), and it is clearly a certification letter, not the full interim report.
2024-08-16 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CFO of PharmaCielo Ltd. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2024. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2981 characters), consistent with a certification letter rather than a full report.
2024-08-16 English
News release - English.pdf
Regulatory Filings
2024-07-17 English
News release - English.pdf
Regulatory Filings
2024-07-17 English
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a press release announcing PharmaCielo's financial results for the fourth quarter and fiscal year ended December 31, 2023, and the first quarter ended March 31, 2024. It includes summary financial data such as revenue, adjusted EBITDA, and net loss for these periods. The document also mentions the filing of the audited annual consolidated financial statements and related management's discussion and analysis (MD&A) on SEDAR, indicating that the full detailed reports are available elsewhere. The text is about 8400 characters, which is substantial but still reads as a summary announcement rather than the full detailed financial report itself. The document also includes management commentary and recent developments but does not contain full financial statements or detailed analysis. According to the rules, initial announcements of quarterly or periodical financial results with key highlights only are classified as Earnings Release (ER). The document fits this category as it provides summarized financial results and commentary but refers to the full reports filed separately. Therefore, the appropriate classification is Earnings Release (ER) with high confidence. Q1 2024
2024-07-04 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CFO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2024. It is a certification letter rather than the interim report itself. The document explicitly states it is a certification and does not contain actual financial data or substantive financial analysis. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR) itself.
2024-07-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.